Thursday, June 19, 2014
metabolic enzyme phosphoribosyl
pyrophosphate synthetase 2 could represent a tractable way to modulate
the notoriously undruggable oncogene MYC.1 The findings from a University of California, San Francisco team are licensed
to Effector Therapeutics Inc. and provide a clue as to how the company plans to attack
protein translation-related mechanisms in cancers.
Ruggero is a cofounder of Effector Therapeutics, and the
new paper is one of the first windows into the targets the company is
attacking. UCSF has filed a patent on the findings, and the IP is licensed to
team at UCSF is collaborating with Kevan Shokat's lab to identify
PRPS2-specific inhibitors. Shokat, also a cofounder of Effector, is chair of
the Department of Cellular and Molecular Pharmacology at UCSF and a Howard Hughes Medical Institute investigator.
Boettner, B. SciBX 7(24);
doi:10.1038/scibx.2014.691 Published online June 19, 2014
1. Cunningham, J.T. et
al. Cell; published online May 22, 2014; doi:10.1016/j.cell.2014.03.052 Contact: Davide Ruggero, University of California, San Francisco, Calif. e-mail:
2. Dang, C.V. Genes
Cancer 1, 526-531 (2010)
AND INSTITUTIONS MENTIONED
Agios Pharmaceuticals Inc. (NASDAQ:AGIO), Cambridge, Mass.
Cancer Research Technology, London, U.K.
Cornerstone Pharmaceuticals Inc., Cranbury, N.J.
Effector Therapeutics Inc., San Diego, Calif.
Howard Hughes Medical Institute, Chevy Chase, Md.
University of California, San Francisco, Calif.
University of California, Los Angeles David Geffen School
of Medicine, Los Angeles,